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NEW STUDY
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Abstract The burden of coronary heart disease (CHD) is
increasing at a greater rate in South Asia than in any other
region globally, but there is little direct evidence about its
determinants. The Pakistan Risk of Myocardial Infarction
Study (PROMIS) is an epidemiological resource to enable
reliable study of genetic, lifestyle and other determinants of
CHD in South Asia. By March 2009, PROMIS had
recruited over 5,000 cases of first-ever confirmed acute
myocardial infarction (MI) and over 5,000 matched con-
trols aged 30–80 years. For each participant, information
has been recorded on demographic factors, lifestyle, med-
ical and family history, anthropometry, and a 12-lead
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electrocardiogram. A range of biological samples has been
collected and stored, including DNA, plasma, serum and
whole blood. During its next stage, the study aims to
expand recruitment to achieve a total of about 20,000 cases
and about 20,000 controls, and, in subsets of participants,
to enrich the resource by collection of monocytes, estab-
lishment of lymphoblastoid cell lines, and by resurveying
participants. Measurements in progress include profiling of
candidate biochemical factors, assay of 45,000 variants in
2,100 candidate genes, and a genomewide association scan
of over 650,000 genetic markers. We have established a
large epidemiological resource for CHD in South Asia. In
parallel with its further expansion and enrichment, the
PROMIS resource will be systematically harvested to help
identify and evaluate genetic and other determinants of MI
in South Asia. Findings from this study should advance
scientific understanding and inform regionally appropriate
disease prevention and control strategies.
Keywords Myocardial Infarction  Case-control study 
South Asia  Pakistan  MI  Risk factors
Introduction
Coronary heart disease (CHD) is the single leading cause
of death worldwide and a major cause of disability [1]. The
projected increase in CHD is expected to be much greater
in South Asia than in any other region worldwide [2],
where it is expected to more than double over the next
20 years [3]. The burden of CHD in South Asians extends
beyond regional concerns, as CHD mortality and morbidity
remain higher in immigrant South Asians living in western
regions compared with native western populations [4].
There is limited evidence, however, about the determinants
of CHD in South Asia, although such evidence should
contribute importantly to scientific understanding and to
the development of regionally appropriate strategies to
prevent and control CHD. In particular, it has been pro-
posed that populations in South Asia are predisposed to
cardiometabolic conditions owing to a combination of
hereditary and lifestyle factors that promote metabolic
dysfunction [5, 6], but direct evidence is sparse.
Until the initiation of the Pakistan Risk of Myocardial
Infarction Study (PROMIS), fewer than 1,000 patients and
a similar number of controls had been assessed in all
available epidemiological studies of CHD in Pakistan, a
country with a population of 175 million. The value of
large case-control studies of CHD in relation to genetic and
lifestyle factors has been demonstrated in non-Pakistani
populations by ISIS (14,000 cases of acute myocardial
infarction (MI), 16,000 controls: [95% white British) [7]
and INTERHEART (15,000 acute MI cases, 15,000
controls: \5% Pakistani) [8]. An important challenge is,
therefore, to establish epidemiological resources of con-
siderable scale in a rigorous yet cost-effective manner in
South Asian populations where there is unmet scientific
and public health need.
The objectives of this report are to describe the methods
used in the establishment of a epidemiological resource for
the study of CHD in Pakistan and to outline the rationale
for the study’s plan of further expansion and sub-studies to
enable scientific enrichment.
Methods
Study participants
PROMIS is a retrospective case-control study of acute MI.
Following screening by medically-qualified research offi-
cers, patients aged 30–80 years admitted to the emergency
rooms of collaborating hospitals (Fig. 1 lists recruitment
centres active as of March 2009) have been eligible for
inclusion as cases if they fulfil all of the following criteria:
(1) sustained clinical symptoms suggestive of MI lasting
longer than 20 min within the previous 24 h; (2) ECG
changes of MI (i.e., new pathologic Q waves, at least 1 mm
ST elevation in any 2 or more contiguous limb leads or a
new left bundle branch block, or new persistent ST–T wave
changes diagnostic of a non-Q wave MI); (3) confirmatory
troponin-T measurements; and (4) no previous cardiovas-
cular diseases, defined as self-reported history of angina,
MI, coronary revascularisation, transient ischaemic attack,
stroke or evidence of CHD on prior ECG or in other
medical records.
Controls have been individuals without a self-reported
history of cardiovascular disease (who had no ECG chan-
ges consistent with a previous MI) drawn from individuals
concurrently identified in the same hospitals as index cases.
Controls have been recruited in the following order of
priority: (1) visitors of patients attending the out-patient
department; (2) patients attending the out-patient depart-
ment for routine non-cardiac complaints, or (3) non-blood
related visitors of index MI cases. Controls were fre-
quency-matched to cases on sex and age (in 5-year bands).
Participants were not recruited into PROMIS if any of the
following features were evident: (1) a previous history of
cardiovascular disease (including self-reported MI, angina,
coronary revascularization, stroke, transient ischaemic
attack, or peripheral vascular disease, and, in cases, pres-
ence of cardiogenic shock); (2) a history of a viral or
bacterial infection in the previous 2 weeks; (3) documented
chronic conditions, such as malignancy, any chronic
infection, leprosy, malaria or other bacterial/parasitic
infections, chronic inflammatory disorders, hepatitis or
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renal failure on past medical history; (4) pregnancy; or (5)
refusal to give consent.
Prior to adoption of the approach described above for
the selection of controls, we carefully assessed several
other options, such as choosing reference groups who had:
an unrelated disease; population based community con-
trols; controls from occupational settings or health-check
clinics. Our chosen approach was considered desirable
because it achieved a balance between feasibility and sci-
entific rigor and because it was scalable in Pakistan. (By
contrast, whereas use of population based community
controls may be desirable in principle, it is considerably
more labour-intensive and expensive and cannot guarantee
that such controls will necessarily represent the catchment
areas from which hospital-based cases are derived, partic-
ularly since referral patterns to hospitals are complex.)
Furthermore, by analogy with the Wellcome Trust Case-
Control Consortium (WTCCC) [9], PROMIS controls can
be efficiently and validly used for patients with other car-
diometabolic conditions owing to the broad geographical
and ethnic scope in PROMIS.
PROMIS has received approval by the relevant research
ethics committee of each of the institutions involved in
participant recruitment. Informed consent has been
obtained from each participant recruited into the study,
including for use of samples in genetic, biochemical and
other analyses.
Questionnaire administration and anthropometry
To maximise consistency and quality-control across
recruitment centres, staff in each recruitment centre have
been trained in the use of standard operating procedures.
Research medical officers have administered pre-piloted
epidemiological questionnaires to participants that seek a
total of [200 items of information in relation to: ethnicity
(e.g, personal and paternal ethnicity, spoken language,
place of birth and any known consanguinity); demo-
graphic characteristics; lifestyle factors (e.g., tobacco and
alcohol consumption, dietary intake and physical activ-
ity); and personal and family history of cardiovascular
disease; and medication usage (Table 1). As dietary habits
and types of tobacco consumption, in particular, can be
substantially different in South Asia than in western
populations, it has been necessary to develop a locally
relevant questionnaire that adequately records such
information (Table 2). Development of the dietary com-
ponent of this questionnaire involved completion of a
24 h dietary recall questionnaire and the completion of a
7-day food diary by 200 healthy adults, which enabled the
identification of 160 different foods consumed that were
categorised into 54 groups by a local nutritionist. A
provisional food-frequency questionnaire was then further
refined after its piloting among 100 additional healthy
adults (e.g., the final version added further questions
about foods typically consumed only during Ramadan, the
month of fasting). For MI cases, questionnaires have been
administered only after medical stabilization and relate to
habits and characteristics during the time before the
diagnosis of acute MI. Using standardized procedures and
equipment, research officers have obtained measurements
of height, weight, waist and hip circumference, systolic
and diastolic blood pressure, and heart rate. Waist cir-
cumference has been assessed over the abdomen at the
widest diameter between the costal margin and the iliac
crest, and hip circumference has been assessed at the level
of the greater trochanters. Research officers have also
recorded a standard 12-lead ECG. Information extracted
from questionnaires, physical measurements and ECG
recordings has been entered by two different operators
Recruitment centre City Predominant 
ethnicity
Punjab Institute of Cardiology Lahore Punjabi
Karachi Urdu
Karachi Urdu
Multan Multan Institute of Cardiology Multan Punjabi
Civil Hospital
Red Crescent Hospital
National Institute of Cardiovascular Diseases
Karachi Institute of Heart Diseases
Hyderabad     
Hyderabad
Sindhi
Urdu
Fig. 1 Location and predominant ethnicities of PROMIS recruitment centres
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onto the central database, which is securely held both in
Karachi, Pakistan, and Cambridge, UK.
Collection of biological samples and initial
biochemistry
Non-fasting blood samples (with the time since last meal
recorded) have been drawn by phlebotomists from each
participant and centrifuged within 45 min of venepuncture.
In MI cases, blood sampling has been due to occur within
24 h of the onset of MI symptoms and prior to the
administration of any thrombolytics, with the time since
onset of symptoms recorded to the nearest hour. Because
blood is collected from MI cases while they are in a
recumbent position (e.g, at about 45), blood samples have
been drawn in the same manner from controls to limit the
possibility of systematic differences (e.g, plasma volumes
may be higher in the supine position than when sitting [10,
11]). A total of 29 ml of blood has been drawn from each
participant in 2 9 6 ml serum tubes and 3 9 5 ml EDTA
Table 1 Summary of questionnaire-based information collected
Type of information Detail recorded
Symptoms, arrival and management
at the hospital
Date of MI, time of onset, time since last meal, review of symptoms, diagnosis and management at the
hospital and any investigations ordered by the attending physician
Medication and medical history Medication class and duration of use for each of anti-coagulant, blood pressure- and lipid-lowering,
diabetes related, hormonal and, for women, contraceptive and HRT medications
Female reproductive history Age at first menstrual period, age periods stopped, hormones for menopause treatment, oral contraceptive
use
Family history Approximate age of diagnosis/occurrence of hypertension, diabetes, angina, MI, stroke, cancer or sudden
death, for each of mother, father, sister, brother, son and daughter
Ethnicity and other genetic related
information
Place of birth, personal and parental ethnicity (e.g, Urdu, Punjabi, Pathan, Balooch, Sindhi, Memon,
Gujrati), parental co-sanguinity
Socio-economic status Occupation(s), monthly income, level and duration of education, marital status, no. of dependants,
ownership/wealth
Physical activity Type, frequency, duration and intensity of activity for each of occupational, work related commuting and
leisure time
Tobacco consumption See Table 2 for details
Psychosocial factors Experience of traumatic events in the past year (e.g., loss of crop, family bereavement), perceived level of
occupational, domestic and financial stress, perceived level of mental and physical health
Anthropometry Height, weight, waist and hip circumference
HRT, hormone replacement therapy
Table 2 Information collected on dietary intake and tobacco consumption
Type of food Routinely recorded information Additional information recorded to reflect local habits
Cooking medium Oil (recording type), butter, margarine Ghee (type of fat)
Breads N/A Naan, chapatti (recording type of flour used), paratha (butter-
coated chapatti)
Fruits and vegetables Separately for cooked and raw, green leafy
vegetables, yellow vegetables, cruciferous
vegetables, salad items, fruits
Method of cooking (grilled, curried and fried)
Meats Chicken, beef, mutton, lamb and fish Method of cooking (grilled, curried and fried)
Legumes Nuts and seeds Pulses (including different daals)
Sweets Bakery items Kheer (dairy based dessert), halwa, mithai, jalabe (unrefined
sugars), nimko (fried desserts)
Brewed beverages Tea, coffee, herbal tea Qahwa (local form of herbal tea)
Other beverages Milk, carbonated and non-carbonated soft drinks,
fruit juices
Alcohol (including local varieties), lassi (yoghurt based drink,
recorded separately for sweet and salty)
Tobacco consumption Usage status, quantity, frequency and lifetime.
Information on sources of passive smoking also
recorded
For each of cigarettes, beedies (rolled tobacco), huqqa (water
pipe), paan (chewing tobacco), naswar (snuff), gutka and
supari (preparations of crushed betel nut, tobacco, and sweet
or savory flavourings).
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tubes (a further citrate tube has been obtained only in
suspected MI cases for troponin assay). Hence, a total of
five blood tubes have been collected per participant,
including serum, EDTA plasma and whole blood which
have been stored in cryogenic vials. All samples have been
stored temporarily at each recruitment centre at -20C. A
second sample (2 ml) has been drawn in cases 10 h after
the onset of clinical symptoms for measurement of tropo-
nin. Serum, plasma and whole blood samples are trans-
ported daily to the local laboratory where they are stored at
-80C. The long-term -80C sample repository is kept in
both Karachi and Cambridge. Measurement of total cho-
lesterol (using an enzymatic colorimetric method, Roche
Diagnostics GmbH, USA) and high-density lipoprotein-
cholesterol (using a homogeneous enzymatic colorimetric
method, Roche Diagnostics GmbH, USA) has been com-
pleted in over 5,000 MI cases and over 5,000 controls thus
far.
DNA quality, quantity and initial genotyping
Research technicians trained in accordance with standard
operating procedures in laboratories in Karachi have
extracted DNA from leucocytes using a reference phenol-
chloroform protocol [12]. PCR-RFLP has been performed
in all samples on the day of extraction to provide an initial
quality check. DNA concentrations have been determined
by fluorescence measurement using PicoGreen molecular
probes. The yield of DNA per participant has typically
been between 600 and 800 ng/ll in a total volume of
about 750 ll. To minimise any systematic biases arising
from plate- or batch-specific genotyping error and/or
nonrandom missingness, stock plates have been used to
generate genotyping plates which contain a mixture of
cases and controls along with negative and positive con-
trols designed to address genotyping quality control (QC),
plate identification and orientation. As part of the QC,
samples have been subject to molecular bar-coding and
checked for degradation by running samples on agarose
gels. Samples passing QC have been diluted in tris borate
EDTA buffer to 50 ng/ll and arrayed into 96-well master
plates.
Further expansion and measurements
By March 2009, PROMIS had recruited over 5,000 con-
firmed first-ever MI cases and over 5,000 controls. The
main objectives of the study’s next stages are: to expand
the study to 20,000 MI cases and 20,000 controls; to enrich
the bioresource in various ways in order to increase its
scientific value; and to accelerate harvesting of its bio-
logical resources. Assays have been completed in the first
2,000 MI cases and in the first 2,000 controls of 45,000
genetic markers in 2,100 candidate genes in the Illumina
Table 3 Biological measurements in progress in PROMIS
Approach Analytical strategy Potential value
Genomics
Genomewide association study Illumina 610 quad array ? 60 K for
CNV analysis
(1) discovery of genetic variants associated with MI; (2) investigation
of genetic architecture in Pakistani population
IBC Illumina cardiochip 45,000 variants selected from 2,100
candidate genes
Comprehensive evaluation of candidate genes in MI
Sequencing In-depth sequencing to investigate LD
structure
Investigation of LD and haplotypes to identify causal genetic variants
Transcriptomics
Genomewide expression study Illumina high throughput beadchip
platform (46,000 gene targets)
(1) assessment of transcript levels associated with cis-acting sequence
variants; (2) comparison of resting and activated transcript levels in
cases and controls; (3) functional consequences of established and
novel variants
Lmyphoblastoid cell lines Transfection with Epstein-Barr virus Functional genomics
Metabonomics
Spectroscopy 1H NMR and GC-MS Metabolic determinants of MI
Biomarkers
Circulating candidate analytes Total cholesterol, HDL-C, LDL-C,
triglycerides, apo-AI, apo-B, Lp(a),
CRP, Lp-PLA2, adiponectin
(1) associations of biomarkers with MI; (2) genetic determinants of
the measured biomarkers in controls
CNV, copy number variants; LD, linkage disequilibrium; 1H NMR, nuclear magnetic resonance; GC-MS, gas chromatography mass spec-
troscopy; HDL-C, high-density lipoprotein cholesterol; LDL-C, low-density lipoprotein cholesterol; apo-AI, apolipoprotein-A1; apo-B, apoli-
poprotein B100; Lp(a), lipoprotein (a); CRP, C-reactive protein; Lp-PLA2, Lipoprotein-associated phospholipase A2
The Pakistan Risk of Myocardial Infarction Study 333
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IBC ‘‘cardiochip’’ array [13]. As part of WTCCC-2, a
genomewide association scan (GWAS) has been conducted
in the first 5,000 MI cases and in the first 5,000 controls
using the Illumina 610-Quad array (including [610,000
SNPs plus 60,000 selected copy number variants) [14]
(Table 3).
Serial epidemiological questionnaires, anthropometry,
and blood sampling is planned in about 1,000 participants
approximately 2–3 years after the initial visit, enabling
quantification of and correction for regression dilution [15,
16]. Such resurveys should also help to validate further the
food-frequency questionnaires developed for use in PRO-
MIS. Pilot studies have already commenced to assess small
metabolites and lipids by mass spectroscopy in plasma
samples (Table 3) [17]. In a subset of participants who will
be part of the GWAS, collection is planned of RNA sam-
ples from monocytes (e.g, Illumina High Throughput
Beadchip platform with 46,000 gene targets) to enable
study of the transcriptome and to elucidate mechanisms by
which sequence variation causes change in gene expression
[18, 19]. In a subset of participants who will have both
GWAS and gene expression data, collection is also planned
of peripheral lymphocytes (using EasySep Human Selec-
tion kits, Stem Cell Technologies, London, UK) that will
be transformed by Epstein-Barr virus for the establishment
of permanent lymphoblastoid cell lines to enable functional
experiments.
Discussion
Although Pakistan is experiencing a substantial increase in
the burden of cardiovascular disease [2, 3], risk factors for
CHD in this population have been relatively little studied
[3, 5, 6, 20, 21]. Before PROMIS, the previous largest
study was INTERHEART-Pakistan, which comprised 650
MI cases and 650 controls [8]. Whereas INTERHEART
has assessed risk factors common to over 50 countries, the
complementary approach in PROMIS has been to focus on
these factors plus a more detailed assessment of distinctive
exposures in Pakistan, notably: indigenous smoking modes
(e.g., beedies, huqqa, naswar); dietary intake (e.g., ghee
consumption, a major source of fat); and a history of
consanguinity. By March 2009, PROMIS had recruited
over 5,000 first-ever confirmed MI cases and over 5,000
controls in whom locally relevant exposure information
had been recorded and from whom various biological
samples had been collected, processed and stored.
PROMIS is addressing two distinct but related strategic
needs. First, the study is estimating the impact of various
modifiable risk factors for MI that should be of considerable
relevance to the prevention and control of cardiovascular
disease in Pakistan, including, as noted above, tobacco
consumption, dietary intake, and physical activity [5, 6,
22, 23]. The second focus of PROMIS is to contribute to
scientific (particularly genetic) discovery in an ethnic-
specific context. Evidence is emerging of variation in the
impact of risk factors in different racial groups, such as a
two-fold higher odds ratios for MI with total cholesterol in
South Asians than Europeans [24]; higher odds ratios for
MI with the LTA4H haplotype in Africans than Europeans
[25]; and relevance of TCF7L2 to type 2 diabetes in West
Africans but not East Asians [26, 27]. The value of large
ethnic-specific studies is illustrated by discovery of the
strongest common susceptibility locus (KCNQ1) yet for
type 2 diabetes, identified in East Asians [28, 29] but not
initially in Europeans because the allele frequency in East
Asians is much higher (40% vs. 5%) despite similar odds
ratios in both races [30]. This highlights how an ethnic-
specific study like PROMIS should reveal entirely new
loci, particularly for low-frequency causal alleles of more
recent origin.
The potentially distinctive risk profile of South Asian
populations [24], together with the apparently earlier onset
of MI and greater familial clustering of CHD [6], reinforces
the need to evaluate directly genetic and other risk factors
in South Asia [1–4]. Despite this need, genetic investiga-
tion of CHD in South Asian populations has hitherto been
limited. By early 2009 at least nine GWAS of clinical
coronary outcomes had been reported, all of which had
been conducted in populations of Northern European or
Japanese ancestry (Table 4) [31–39]. None of these had
adequate statistical power to detect reliably odds ratios
with common variants of 1.5 or smaller. To our knowledge,
at least three studies are currently conducting GWAS for
CHD in South Asians: PROMIS (5,000 confirmed MI cases
and 5,000 controls in urban Pakistan), LOLIPOP (3,500
cases of MI and/or coronary stenosis and 4,000 controls in
London, UK) [40] and INTERHEART (400 MI cases and
400 controls in South Asia) [8]. These (and other) studies
should yield novel insights into the genetic determinants of
CHD in South Asians, particularly in potential eventual
combined analyses of data. In addition to the GWAS,
PROMIS is concomitantly attempting other discovery
approaches (e.g, metabolomics employing 1H-nuclear
magnetic resonance spectroscopy and gas-chromatography
mass spectroscopy), and functional studies. Data from
these complementary methods are likely to enhance bio-
logical insights, particularly with the application of
emerging statistical techniques for systems biology [41,
42].
The strengths and potential limitations of PROMIS
merit consideration. Retrospective case-control studies of
MI can usefully complement prospective studies because
the former involve ascertainment of exposure information
and blood sampling of people who have already developed
334 D. Saleheen et al.
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MI and a comparable group of controls without MI,
enabling rapid and cost-effective accrual of large numbers
of relevant cases. By contrast, prospective studies need
several hundred thousand people to be screened (with all of
their blood samples kept in frozen storage) and followed
for at least one or two decades in order to accrue about
20,000 MI cases. Furthermore, retrospective studies are
often able to include large numbers of individuals who
have developed the disease at younger ages, when associ-
ations with risk factors are often stronger, providing par-
ticularly sensitive tests of certain hypotheses. As
demonstrated by the WTCCC [9], case-control studies can
powerfully and efficiently facilitate genetic discovery and
can use GWAS data to quantify and robustly correct for
any population structure [43].
The ISIS and INTERHEART studies have, moreover,
demonstrated that appropriately conducted, large case-
control studies can usefully address some nongenetic
hypotheses in MI, such as tobacco and alcohol consump-
tion, and serological evidence of infection [7–9, 44–46].
Nevertheless, particularly in relation to nongenetic
hypotheses, retrospective case-control studies may be lia-
ble to potential biases, such as recall bias (although there
may be less scope for such bias in a study of acute MI than
in a study of chronic stable CHD, as hours rather than
months or years have elapsed since the index event) and
selection biases. As noted earlier, selection of controls in
case-control studies invariably involves trade-offs between
scientific rigor and feasibility. Following the example of
INTERHEART [8], we have opted to recruit controls
drawn from attendants of people visiting out-patient clinics
or (non-blood-related) attendants of cardiac patients; these
groups will be compared in sensitivity analyses. Studies of
plasma components may be affected by case-control stud-
ies of acute MI because certain circulating markers may be
altered by sampling of blood within 24 h of MI symptoms.
If as in PROMIS, time since the onset of symptoms has
been recorded, any material bias can be quantified and at
least partially corrected for. Similar considerations apply to
fasting status and the recording of time since last meal [7,
44].
Conclusion
PROMIS is a large epidemiological resource for CHD in
South Asia that will be systematically harvested to help
identify and evaluate genetic and other determinants of MI
in South Asia. It should help to hasten discovery of disease-
causing pathways and to inform regionally appropriate
strategies that optimise public health action in a country
with limited resources.
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